<bill session="117" type="s" number="4340" updated="2022-12-29T16:48:33Z">
  <state datetime="2022-05-26">REFERRED</state>
  <status>
    <introduced datetime="2022-05-26"/>
  </status>
  <introduced datetime="2022-05-26"/>
  <titles>
    <title type="display">EFFECTIVE Act</title>
    <title type="short" as="introduced">EFFECTIVE Act</title>
    <title type="short" as="introduced">Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act</title>
    <title type="official" as="introduced">A bill to allow the Secretary of Health and Human Services to deny approval of a new drug application for an opioid analgesic drug on the basis of such drug not being clinically superior to other commercially available drugs.</title>
  </titles>
  <sponsor bioguide_id="M001183"/>
  <cosponsors>
    <cosponsor bioguide_id="B001310" joined="2022-05-26"/>
  </cosponsors>
  <actions>
    <action datetime="2022-05-26">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2022-05-26" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="8586" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-11-14T16:53:11Z" status="Introduced in Senate">Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act or the EFFECTIVE Act

This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug upon a determination that the drug does not provide a significant advantage or clinical superiority compared to other drugs.</summary>
</bill>
